2Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening : a perspective from bioavailability enhancement [ J ]. Pharmaeol Res ,2003 ,48 (4) : 347 -359.
3Loo TW, Clarke DM. Location of the rhodamine-binding site in the humanmultidrug resistance P-glycoprotein [ J ]. J Biol Chem, 2002, 277 (46) :44332-44338.
4Chevillard S, Pouillart P, Beldjord C, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chem- otherapy[J]. Cancer, 1996,77(2) :292-300.
5Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a trans- porter gene in a muhidrug-resistant human lung cancer cell line[ J]. Science, 1992,258 (5088) : 1650-1654.
6Versantvoort CH, Withoff S, Broxterman H J, et al. Resistance-associated factors in human small-cell lung-carcinoma GLCg sublines with increasing adriamycin resistance [ J ]. Int J Cancer, 1995,61 ( 3 ) : 375-380.
7Brock I, Hipfner DR, Nielsen BS, et al. Sequential coexpression of the multidrug resistance genes MRP and mdrl and their products in VP216 ( etoposide ) 2selected H69 small cell lung cancer cells [ J ]. Cancer Res, 1995,55 (3) :459-462.
8Versantvoort CH, Broxterman HJ, glutathione of drug transport in Bagrij T, et al. Regulation by muhidrug-resistant human lung tumour cell lines overexpressing multidrug tein[ J]. Br J Cancer,1995,72( 1 ) :89. pro-.
9Scheper R J, Broxterman H J, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated muhidrug resistance[ J]. Cancer Res, 1993,53 (7) : 1475-1479.
10Kawabata S, Oka M, Shiozawa K, ct al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells [ J ]. Biochem Biophys Res Commun,2001,280(5) :1216-1223.
3Stein U,Walther W.Cytokine-mediated reveral of multidrug resis-tance[J].Cytoteh,1998,27(1-3):271-282.
4Haus-Cohen M,Assaraf Y G,Binyamin L,et al.Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment tragment targeted to an extracellular epitope[J].Int J Cancer,2004,109(5):750-758.
5Marzolini C,Paus E,Buclin T,et al.Polymophisms in human MDR1 (P-glycoprotein):recent advances and clinical relevance[J].Clin Phamacol Ther,2004,75(1):13-33.
7Stupp R,Bauer J,Pagani O,et al.Ventricuar arrhythmia and torsade de pointe:dose limiting toxicities of the MDR-modulator S9788 in a phase Ⅰ trial[J].Ann Oncol,1998,9(11):1233-1242.
8Francois H,Catherine V,Pierre D V,et al.In vitro and in vivo reversal of multidrug resistance by GF120918,an acridonecarboxa-mide derivative[J].Cancer Res,1993,53(19):4595-4602.
9Dantzig A,Shepard R,Cao J,et al.Reversal of P-glyco-protein med-iated multidrug resistance by a potent cyclopropyl dibenzo suberane modulator,LY 335979[J].Cancer Res,1996,56(18):4171-4179.
10VanZuylen L,Sparreboom A,VanDer G A,et al.The orally adminis-tered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel[J].Clin Cancer Res,200,6(4):1365-1371.
